Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFatigue is one of the most commonly reported side effects of tirzepatide, and it is listed in the Mounjaro Patient Information Leaflet as an expected possibility. Most people who feel very tired on Mounjaro notice it in the first few weeks of treatment (or in the days after a dose increase) and it tends to ease as the body adjusts. It does not mean the medicine is harming you, and it does not mean you need to stop. But it does deserve a closer look, because the right response depends on what is driving it. These are prescription-only medicines; a prescriber who knows your full picture is the right person to guide any changes to your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people contact their prescribers about feeling exhausted on Mounjaro, the conversation almost always starts with the same question: is this the medicine, or is something else happening? That is the right question to ask, and it is worth unpacking before assuming the answer.
Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, that are involved in appetite signalling and glucose regulation. Slowing gastric emptying and reducing hunger are the intended effects. But those same mechanisms can leave people eating significantly less than their body is used to, and a meaningful calorie deficit (especially a sudden one) produces real physical tiredness. It is not imaginary, and it is not a sign of weakness. It is your body adjusting to a different energy balance.
On top of that, GI side effects such as nausea or disrupted digestion can interrupt sleep, and broken sleep compounds daytime fatigue in ways that feel out of proportion to how unwell you actually feel. The full side-effect profile of Mounjaro is broader than most people expect when they start, fatigue sits alongside nausea, headache and dizziness as common early companions.
So the decision in front of you is not simply "stop or continue". It is: understand what is driving the tiredness, make the adjustments within your control, and know the thresholds that should send you back to a clinician promptly. The sections below walk through each of those in turn.
Reduced food intake is the single most overlooked cause of tiredness during GLP-1 treatment. When appetite drops sharply, many people eat far less without realising it, and protein in particular takes a hit. Muscle tissue needs adequate protein to maintain itself, and when it does not get enough, energy levels fall. Prioritising protein at meals (even when appetite is low) is one of the most practical things you can do. Small, frequent portions tend to work better than trying to eat a full meal when nausea is making that difficult.
Hydration matters more than most people expect. Tirzepatide slows gastric emptying, which can reduce the natural drive to drink, and mild dehydration produces fatigue that is easily mistaken for a medicine side effect. Sipping water consistently through the day, rather than trying to drink large amounts at once, is easier on a slowed digestive system.
Dose timing can also help. Some people find that injecting later in the day means any peak side effects arrive overnight rather than during working hours. That said, when to inject is a prescriber decision based on your individual plan, raise it at your next review rather than changing it unilaterally. For a broader picture of how the medicine works and what to expect across the treatment course, the Mounjaro overview at nume covers the full picture in plain language.
One misconception worth letting go of: fatigue does not mean the medicine is working less well, or that you need a higher dose sooner. The two are unrelated. If you want to understand exactly why this happens and what the pattern typically looks like, our guide to feeling tired on Mounjaro covers the causes, timeline and practical steps in detail.
Most tiredness on Mounjaro is manageable and self-limiting. But there are patterns that warrant earlier contact with your prescribing team or GP, and knowing them is important.
Severe, persistent stomach pain that spreads to the back (with or without vomiting) is not fatigue. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and that symptom pattern is the one to act on quickly. Do not wait to see if it passes.
Signs of significant dehydration (dark urine, dizziness on standing, very little output) combined with tiredness suggest the GI side effects have tipped into something that needs assessment. Similarly, fatigue accompanied by persistent low mood, loss of interest in things, or thoughts of self-harm is not a medicine side effect to manage at home; it needs a conversation with a clinician the same day.
If tiredness is your only symptom and it has been present for more than two to three weeks without improving, that is also worth raising, partly to rule out other causes such as anaemia or thyroid changes, which have nothing to do with Mounjaro and are worth checking if they have not been recently. The NHS provides clear guidance on tirzepatide side effects at nhs.uk/medicines/tirzepatide, including what to watch for and when to seek help.
People wondering whether fatigue is more pronounced at particular doses will find the question explored in depth on our tirzepatide and tiredness page, and those earlier in their research may find the overview of whether tiredness is expected on Mounjaro a useful starting point.
Tiredness alone rarely means Mounjaro needs to be stopped. What it often means is that the treatment plan needs a small adjustment: a slower titration, a conversation about nutrition, a check that nothing unrelated is going on in the background.
A prescriber can also assess whether the fatigue pattern fits what is expected at your current dose, review whether a dose increase is appropriate given your response so far, and flag any interactions or health factors that might be adding to tiredness. That is the kind of clinical judgement that cannot be replaced by reading a list of common side effects, however thorough.
If you are already on Mounjaro through a GP or another service and have concerns right now, your prescribing team is the first port of call. If you are considering starting treatment and want to understand what the experience is likely to look like before committing, a consultation with a clinical team that reviews applications the same day (not via an algorithm) is the sensible first move. The weight-loss treatment options at nume explain what the process looks like from first enquiry to delivery.
Our prescribers also handle questions about managing side effects as part of ongoing aftercare, available seven days a week. For context on what private Mounjaro treatment typically costs alongside what that covers, Mounjaro pricing in the UK lays out what to expect and what questions to ask of any provider.
If you are ready to speak to a prescriber, start your free consultation and a GPhC-registered Independent Prescriber will review your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.